These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 34703298)

  • 1. Pain Management and Opioid Therapy: Persistent Knowledge Gaps Among Primary Care Providers.
    Williamson C; Martin BJ; Argoff C; Gharibo C; McCarberg B; Atkinson T; Berger L; Sullivan T
    J Pain Res; 2021; 14():3223-3234. PubMed ID: 34703298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary care physician opinion survey on FDA opioid risk evaluation and mitigation strategies.
    Slevin KA; Ashburn MA
    J Opioid Manag; 2011; 7(2):109-15. PubMed ID: 21561034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase your Confidence in Opioid Prescribing: Marketing Messages in Continuing Medical Education Activities on ER/LA Opioids.
    Goodwin B; Lim HD; Butler J; Paglia D; Dempsey MT; O Connor B; Fugh-Berman A
    Pain Physician; 2021 Aug; 24(5):E529-E538. PubMed ID: 34323440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCOPE of Pain: An Evaluation of an Opioid Risk Evaluation and Mitigation Strategy Continuing Education Program.
    Alford DP; Zisblatt L; Ng P; Hayes SM; Peloquin S; Hardesty I; White JL
    Pain Med; 2016 Jan; 17(1):52-63. PubMed ID: 26304703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What do providers want to know about opioid prescribing? A qualitative analysis of their questions.
    Cushman PA; Liebschutz JM; Hodgkin JG; Shanahan CW; White JL; Hardesty I; Alford DP
    Subst Abus; 2017; 38(2):222-229. PubMed ID: 28394736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of opioid safety initiatives, prescribing patterns for opioid and naloxone, and perceived barriers to prescribing naloxone: Cross-sectional survey results based on practice type, scope, and location.
    Kohan LR; Elmofty D; Pena I; Liao C
    J Opioid Manag; 2021; 17(1):19-38. PubMed ID: 33735425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beliefs and attitudes about prescribing opioids among healthcare providers seeking continuing medical education.
    Hooten WM; Bruce BK
    J Opioid Manag; 2011; 7(6):417-24. PubMed ID: 22320023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ER/LA opioid REMS and accredited education: Survey results provide insight into clinical roles, educational needs, and learner preferences.
    Kear C; McKeithen T; Robertson S
    Subst Abus; 2017; 38(2):145-149. PubMed ID: 28418777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safe and competent opioid prescribing education: Increasing dissemination with a train-the-trainer program.
    Zisblatt L; Hayes SM; Lazure P; Hardesty I; White JL; Alford DP
    Subst Abus; 2017; 38(2):168-176. PubMed ID: 28418816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines.
    Manchikanti L; Kaye AM; Knezevic NN; McAnally H; Slavin K; Trescot AM; Blank S; Pampati V; Abdi S; Grider JS; Kaye AD; Manchikanti KN; Cordner H; Gharibo CG; Harned ME; Albers SL; Atluri S; Aydin SM; Bakshi S; Barkin RL; Benyamin RM; Boswell MV; Buenaventura RM; Calodney AK; Cedeno DL; Datta S; Deer TR; Fellows B; Galan V; Grami V; Hansen H; Helm Ii S; Justiz R; Koyyalagunta D; Malla Y; Navani A; Nouri KH; Pasupuleti R; Sehgal N; Silverman SM; Simopoulos TT; Singh V; Solanki DR; Staats PS; Vallejo R; Wargo BW; Watanabe A; Hirsch JA
    Pain Physician; 2017 Feb; 20(2S):S3-S92. PubMed ID: 28226332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioids for chronic pain: a knowledge assessment of nonpain specialty providers.
    Pearson AC; Eldrige JS; Moeschler SM; Hooten WM
    J Pain Res; 2016; 9():129-35. PubMed ID: 27022300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A safe in-home disposal system with every opioid prescription? Food and Drug Administration is considering a potential new Risk Evaluation and Mitigation Strategy that could impact pharmacists.
    Stubbings J; Crawford SY; Menighan TE
    J Am Pharm Assoc (2003); 2022; 62(2):413-418. PubMed ID: 34872856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ER/LA Opioid Analgesics REMS: Overview of Ongoing Assessments of Its Progress and Its Impact on Health Outcomes.
    Cepeda MS; Coplan PM; Kopper NW; Maziere JY; Wedin GP; Wallace LE
    Pain Med; 2017 Jan; 18(1):78-85. PubMed ID: 27373304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Examination of State and Federal Opioid Analgesic and Continuing Education Policies: 2016-2018.
    Duensing K; Twillman R; Ziegler S; Cepeda MS; Kern D; Salas M; Wedin G
    J Pain Res; 2020; 13():2431-2442. PubMed ID: 33061558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.
    Stanos S
    Phys Sportsmed; 2012 Nov; 40(4):12-20. PubMed ID: 23306411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The changing landscape of opioid prescribing: long-acting and extended-release opioid class-wide Risk Evaluation and Mitigation Strategy.
    Gudin JA
    Ther Clin Risk Manag; 2012; 8():209-17. PubMed ID: 22570553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice.
    Gudin J
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):136-43. PubMed ID: 22764852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physician survey examining the impact of an educational tool for responsible opioid prescribing.
    Young A; Alfred KC; Davignon PP; Hughes LM; Robin LA; Chaudhry HJ
    J Opioid Manag; 2012; 8(2):81-7. PubMed ID: 22616313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products.
    Rollman JE; Heyward J; Olson L; Lurie P; Sharfstein J; Alexander GC
    JAMA; 2019 Feb; 321(7):676-685. PubMed ID: 30778596
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.